Lipid lowering drugs in diabetes: Lipid lowering has ophthalmic benefits [3]

British Medical Journal

Volumn 332, Issue 7552, 2006, Pages 1272-1273

  Sheth, Hiten G ^a   Aslam, Sher ^a   Davies, Nigel ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FENOFIBRATE; PLACEBO; ANTILIPEMIC AGENT;

ARGON LASER; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG EFFECT; HUMAN; LETTER; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; HYPERLIPIDEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; RETINA MACULA DEGENERATION;

ANTILIPEMIC AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HUMANS; HYPERLIPIDEMIAS; MACULAR DEGENERATION;

EID: 33744969592     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Costa J, Borges M, David C, Carneiro AV. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332:1115-8. (13 May.)
2. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular oedema. Am J Ophthalmol 2004;137:675-82.
3. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989;107:244-49.
4. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-84.
5. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus: randomised controlled trial. Lancet 2005;366:1849-61.